Attrition in drug court research: Examining participant characteristics and recommendations for follow-up.

J Forensic Soc Work

Amherst Town Drug Court, 400 John James Audubon Pkwy. Amherst, NY 14228. Ph: 716-689-4249.

Published: January 2013

Drug court research is often challenged by study attrition. In this study, researchers attempted to predict study completion using variables traditionally associated with treatment attrition. Findings showed that participants who reported a need for additional help to resolve legal problems and who reported accessing outpatient treatments were more likely to complete the study at the three-month follow-up. The study also demonstrated a relationship between trauma-related symptoms and study attrition. Although sample size was a limitation with these pilot data, researchers are urged to examine attrition and increase efforts to engage drug court enrollees in research studies, especially those with trauma-related symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902036PMC
http://dx.doi.org/10.1080/1936928X.2013.837418DOI Listing

Publication Analysis

Top Keywords

drug court
12
study attrition
8
trauma-related symptoms
8
study
6
attrition
5
attrition drug
4
court examining
4
examining participant
4
participant characteristics
4
characteristics recommendations
4

Similar Publications

Background: Optimal management of anaemia following surgery for colorectal cancer remains unclear. Peri-operative anaemia is common in patients undergoing resectional surgery for colorectal cancer. A significant amount of research has been conducted into the management of pre-operative anaemia; however, little work has investigated post-operative anaemia.

View Article and Find Full Text PDF

In 2021, the sole paragraph of article 40 of the Industrial Property Law (LPI) was declared unconstitutional. As a result, some companies filed lawsuits seeking an extension of the term of validity of their pharmaceutical patents. This article aims to estimate the possible economic consequences of the extension of the term of patents in spending on medicines for centralized procurement and the private market.

View Article and Find Full Text PDF

Cannabicyclol ((±)-CBL), a minor phytocannabinoid, is largely unexplored, with its biological activity previously undocumented. We studied its conversion from cannabichromene (CBC) using various acidic catalysts. Montmorillonite (K30) in chloroform at room temperature had the highest yield (60%) with minimal byproducts.

View Article and Find Full Text PDF

Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors determine the length of treatment required for durable cure in individual patients would allow individualization of treatment durations, provide better clinical tools to determine the of appropriate duration of new regimens, as well as reduce the cost of large Phase III studies to determine the optimal combinations to use in TB control programs. We conducted a randomized clinical trial in South Africa and China that recruited 704 participants with newly diagnosed, drug-sensitive pulmonary tuberculosis and stratified them based on radiographic disease characteristics as assessed by FDG PET/CT scan readers.

View Article and Find Full Text PDF

Drug courts are specialized programs from the courts that aim to offer a chance to individuals with substance-related problems encountering law enforcement to take treatment rather than face incarceration. The aim of this debate is to critically debate the utility, applicability, and feasibility of drug courts in India. This is a theoretical debate based on the existing evidence and considerations of ground realities in the country.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!